SSA
CODX

Schonfeld Strategic Advisors’s Co-Diagnostics CODX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,023
Closed -$172K – 2983
2022
Q2 		$172K Buy
+1,023
New +$156K ﹤0.01% 1956
2021
Q4 		– Sell
-595
Closed -$174K – 2197
2021
Q3 		$174K Buy
595
+115
+24% +$33.6K ﹤0.01% 1809
2021
Q2 		$118K Buy
+480
New +$123K ﹤0.01% 1780

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Schonfeld Strategic Advisors's CODX Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Co-Diagnostics (CODX) in Q3 2022, closing a stake of 1,023 shares — an estimated $172K sold.

Schonfeld Strategic Advisors first reported a position in CODX in Q2 2021 and held it in 3 quarters. The position peaked at $174K in Q3 2021. 65 funds tracked by Wall St. Rank hold CODX as of Q3 2022.

  • Schonfeld Strategic Advisors reported no remaining Co-Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 1,023 Co-Diagnostics shares in Q3 2022, an estimated $172K.
  • Schonfeld Strategic Advisors first reported a position in Co-Diagnostics in Q2 2021 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Co-Diagnostics position peaked at $174K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.